Scopoletin potentiates the anti-cancer effects of cisplatin against cholangiocarcinoma cell lines

Authors

  • Md. Ali Asgar Program in Biological Science, Khon Kaen University, Khon Kaen 40002
  • Gulsiri Senawong Department of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen 40002
  • Banchob Sripa Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002
  • Thanaset Senawong Program in Biological Science, Khon Kaen University, Khon Kaen 40002

DOI:

https://doi.org/10.3329/bjp.v10i1.21202

Keywords:

Cholangiocarcinoma, Cisplatin, Drug combination, Scopoletin

Abstract

Chemotherapy with cisplatin in cholangiocarcinoma produces adverse effects and leads to resistance development by tumors. We aimed to evaluate anti-cancer effects by co-administration of cisplatin and scopoletin in cholangiocarcinoma cells. MTT assay, median effect principle, cell cycle arrest and apoptosis assay were conducted to determine anti-cancer effects. Results revealed that treatment with cisplatin and scopoletin resulted in dose-dependent reduction of cell viability for cholangiocarcinoma cells. Combination of these agents inhibited proliferation of cells significantly more than single agent either. Combination indices reflect additive cytotoxic effect, leading to >2 times dose reduction for each agent. Both the cell cycle arrest (G0/G1) and apoptosis induction underling the enhanced cytotoxicity for the combination. Besides, single agent conferred cell cycle arresting and apoptotic effects in cholangiocarcinoma cells. By contrast, non-cancer cells were less affected with combination. Our observations suggest that cisplatin and scopoletin combination may bring positive significance in cholangiocarcinoma treatment.

Downloads

Download data is not yet available.
Abstract
601
Download
190 Read
266

Downloads

Additional Files

Published

2015-01-21

How to Cite

Asgar, M. A., G. Senawong, B. Sripa, and T. Senawong. “Scopoletin Potentiates the Anti-Cancer Effects of Cisplatin Against Cholangiocarcinoma Cell Lines”. Bangladesh Journal of Pharmacology, vol. 10, no. 1, Jan. 2015, pp. 69-77, doi:10.3329/bjp.v10i1.21202.

Issue

Vol. 10 No. 1 (2015)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).